Healio26 分钟
Lepodisiran lowers Lp(a) substantially with infrequent administration
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate ...
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending ...